Bionano Genomics Appoints Helene Klein as its First Ever Chief People Officer
February 14 2022 - 08:00AM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of NxClinical™,
the leading software solution for visualization, interpretation and
reporting of genomic data, today announced that it has appointed
Helene Klein as its chief people officer, further strengthening its
leadership team. As the company expands, culture and employee
experience become key success factors. The appointment of a chief
people officer today reflects Bionano’s focus on maintaining and
evolving its culture of innovative, disciplined, and rapid response
to market needs.
Ms. Klein was formerly the chief people officer at the Beachbody
Company (NYSE: BODY) where she led the people function for 14
years. During her time there as CPO, the Beachbody employee
population scaled from 150 employees to over 1100 in three
countries, revenue grew from $150M to over $1B annually, and the
company went public on the New York Stock Exchange. Prior to
Beachbody, Ms. Klein held senior leadership roles in human
resources in multiple global companies and industries, including
healthcare, retail and consumer products.
In this new position, Ms. Klein will be responsible for leading
human resources, employer branding, and Bionano’s diversity, equity
and inclusion program. She will also be responsible for all aspects
of Bionano’s employee experience, including attracting, engaging,
and retaining talent to support Bionano’s continued growth.
“I am pleased to welcome Helene to Bionano and thank her for
embracing our why, which is to elevate human health and wellness by
transforming the way the world sees the genome,” commented Erik
Holmlin, PhD, president and chief executive officer of Bionano
Genomics. “Her breadth of experience and track record, especially
at Beachbody, make her well-suited for creating one of the best
employee experiences in the industry. All of us on the senior
leadership team are really looking forward to partnering with
Helene to amplify the incredible capabilities of our people and
propel us to reach new heights.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
bionanogenomics.com, lineagen.com or biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the impacts of Ms.
Klein’s hiring on Bionano’s workforce. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; hiring
efforts may not achieve the desired results; changes in our
strategic and commercial plans; our ability to obtain sufficient
financing to fund our strategic plans and commercialization
efforts; the ability of medical and research institutions to obtain
funding to support adoption or continued use of our technologies;
and the risks and uncertainties associated with our business and
financial condition in general, including the risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2020 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Beachbody (NYSE:BODY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Beachbody (NYSE:BODY)
Historical Stock Chart
From Mar 2023 to Mar 2024